

p-Measles virus (9H4): sc-101356

BACKGROUND

Measles virus (MV), also known as rubeola, is an acute viral illness that can be complicated by severe pneumonia, diarrhea and encephalitis. A paramyxovirus of the genus *Morbillivirus*, Measles virus is an enveloped and nonsegmented negative-stranded RNA virus. Because it is spread through respiration, Measles virus is highly contagious and airborne precautions should be taken for all suspected cases. The incubation period of the virus, during which there are no symptoms, normally lasts for 4-12 days. Infected people continue to be contagious from the initial symptoms until 3-5 days after a maculopapular rash appears. After transmission, the virus infects the epithelial cells of its new host, and may also replicate in the urinary tract, conjunctivae, blood vessels, lymphatic system and central nervous system. Humans and various monkey species remain the only known hosts of measles. Measles virus contains two envelope glycoproteins, the haemagglutinin (H) and fusion proteins, which are responsible for membrane fusion and attachment. Measles virus contains a protein that represses genome replication, protein V, which may function as an RNA-binding modulatory factor.

REFERENCES

1. Parks, C.L., Witko, S.E., Kotash, C., Lin, S.L., Sidhu, M.S. and Udem, S.A. 2006. Role of V protein RNA binding in inhibition of Measles virus minigenome replication. *Virology* 348: 96-106.
2. Iankov, I.D., Pandey, M., Harvey, M., Griesmann, G.E., Federspiel, M.J. and Russell, S.J. 2006. Immunoglobulin G antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. *J. Virol.* 80: 8530-8540.
3. Yanagi, Y., Takeda, M. and Ohno, S. 2006. Measles virus: cellular receptors, tropism and pathogenesis. *J. Gen. Virol.* 87: 2767-2779.
4. Vijayaraghavan, M., Martin, R.M., Sangruejee, N., Kimani, G.N., Oyombe, S., Kalu, A., Runyago, A., Wanjau, G., Cairns, L. and Muchiri, S.N. 2006. Measles supplemental immunization activities improve measles vaccine coverage and equity: Evidence from Kenya, 2002. *Health Policy* 83: 27-36.
5. Halsey, N.A. 2006. Measles in developing countries. *BMJ* 333: 1234.
6. Centers for Disease Control and Prevention (CDC). 2006. Measles—United States, 2005. *MMWR Morb. Mortal. Wkly. Rep.* 55: 1348-1351.
7. Bradsher, C.A., Stotts, R.C., Carter, M.A. and Grabowsky, M. 2007. The measles initiative to control measles in Kenya. *Public Health Nurs.* 24: 26-33.
8. Moss, W.J. 2007. Measles still has a devastating impact in unvaccinated populations. *PLoS Med.* 4: e24.

STORAGE

For immediate and continuous use, store at 4° C for up to one month. For sporadic use, freeze in working aliquots in order to avoid repeated freeze/thaw cycles. If turbidity is evident upon prolonged storage, clarify solution by centrifugation.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SOURCE

p-Measles virus (9H4) is a mouse monoclonal antibody raised against a recombinant phosphoprotein of Measles virus.

PRODUCT

Each vial contains 50 µg IgG₁ in 0.5 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

p-Measles virus (9H4) is recommended for detection of phosphorylated Measles virus by Western Blotting (starting dilution to be determined by researcher, dilution range 1:100-1:5000), immunofluorescence (starting dilution to be determined by researcher, dilution range 1:50-1:2500), immunohistochemistry (including paraffin-embedded sections) (starting dilution to be determined by researcher, dilution range 1:50-1:2500) and solid phase ELISA (starting dilution to be determined by researcher, dilution range 1:100-1:5000).

SELECT PRODUCT CITATIONS

1. Benharroch, D., Ariad, S., Tadmor, N., Nalbandyan, K. and Lazarev, I. 2016. Relevance of the Measles virus expression in Cancer—an update. *Pathol. Oncol. Res.* 22: 661-666.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.